In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...